Healthcare Checkup

Early detection of cancer.

Cancer Finder

1. Simple Test

Detection of multiple cancer types
through a simple blood test

- 8 solid cancer types (colorectal, gastric, liver, pancreatic, lung, breast, ovarian, prostate) are examined simultaneously in one blood draw.

- By detecting abnormal characteristics of the genome derived from cancer cells, it is possible to determine the presence or absence of cancer-derived DNA and predict the primary tumor site based on those characteristics.

2. Accurate Analysis

Genome precision analysis using latest artificial intelligence (AI) techniques

- Genome data based on next-generation sequencing (NGS) and analysis technology using artificial intelligence provide fast and accurate results.

- In order to find a trace amount of cancer-derived DNA, various characteristics that appear throughout the genome are comprehensively analyzed. In particular, it maximizes performance by comprehensively analyzing the characteristics of methylation, CNV, and DNA fragments, which are known to reflect the differences between cancer types.

Recommended for

Adults seeking cancer screening at early stage.
Individuals with a family history of cancer or concerns about cancer development.
Adults willing to take cancer screening tests but fear invasive endoscopy or imaging tests with radiation exposure.
Individuals needing further testing because of inconclusive results from other screening tests.

CancerFind detect 8 cancer types

with a simple blood draw

CancerFind Test Process

Blood Sampling

A Simple Blood Draw

20mL of blood is sampled for the CancerFind test.

The blood is Stored in dedicated cfDNA tube.

Blood Sampling

Advanced AI-Driven Genomic Precision Analysis

cfDNA in the blood is extracted and amplified to run Next Generation Sequencing for detecting mutations.



Blood Sampling

Results delivered in 3 weeks

The presence or absence of ctDNA is delineated. When a cancer signal is detected, information regarding the predicted primary tumor site is provided.

Features of CancerFind

Cancer is initially very small in size, only a trace amount of circulating tumor-derived DNA exist in the blood. To detect cancer early, it is crucial to comprehensively analyze changes in the genome that occur due to cancer across a wide range. CancerFind has maximized the performance of early cancer detection through innovative next-generation liquid biopsy analysis technology.

VS. Imaging Tests

Imaging test requires separate tests for different organs and can be challenging to repeat regularly. Furthermore, they have limitations in detecting small-sized cancers at an early stage.

CancerFind test conducted through a convenient blood draw. and enable to detect cancers smaller than 1cm in size.

VS. Protein tumor markers

Conventional blood protein cancer markers(e.g., CEA, CA- 19-9, PSA, etc.) can increase due to factors other than cancer, leading to a notable false-positive ratio and reduced accuracy.

·CancerFind enables accurate detection of cancer signal by analyzing multi-omics genomic patterns of ctDNA.

VS. Conventional blood- based hereditary cancer tests

Conventional blood-based hereditary cancer tests indirectly examine genetic mutations related to hereditary cancers in blood cells, not directly derived from cancer cells. These indirect tests cannot confirm the presence of cancer at the time of testing.

·CancerFind directly analyzes the characteristics of ctDNA in real-time with high accuracy and specificity.

Our Solutions

AlphaLiquid®

Service

Company